Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.38 |
| ▸ | SRC | P12931 | 2/20 | 0.37 |
| ▸ | KIT | P10721 | 2/20 | 0.37 |
| ▸ | FLT3 | P36888 | 2/20 | 0.37 |
| ▸ | CASP7 | P55210 | 1/20 | 0.36 |
| ▸ | CASP6 | P55212 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | HTR1D | P28221 | 1/20 | 0.36 |
| ▸ | HTR1B | P28222 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL425347 | 0.88 | DDR2 (0.42) | SIGMAR1DDR2CASP7CASP6MAPK14 | |
| SCHEMBL425345 | 0.88 | DDR2 (0.42) | SIGMAR1DDR2CASP7CASP6MAPK14 | |
| SCHEMBL425820 | 0.87 | MRGPRX4 (0.47) | SIGMAR1DDR2CASP7CASP6KDR | |
| SCHEMBL426673 | 0.86 | MAPT (0.42) | SIGMAR1HTR2BDDR2KITFLT3 | |
| SCHEMBL425402 | 0.86 | KMO (0.45) | SIGMAR1DDR2MAPK14 | |
| SCHEMBL430391 | 0.86 | DDR2 (0.42) | SIGMAR1HTR2BDDR2MAPK14 | |
| SCHEMBL425404 | 0.86 | KMO (0.45) | SIGMAR1DDR2MAPK14 | |
| SCHEMBL430389 | 0.86 | DDR2 (0.42) | SIGMAR1HTR2BDDR2MAPK14 | |
| SCHEMBL425298 | 0.84 | L3MBTL1 (0.48) | SIGMAR1CASP7CASP6 | |
| SCHEMBL425301 | 0.84 | CASR (0.42) | SIGMAR1DDR2CASP7CASP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120021434-A1 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS | SYNTA PHARMACEUTICALS CORP. (US) | 2012-01-26 | — | — | US | disclosed |